However, the inherent lack of specificity of CRP limits its utility as a standalone tumor marker, necessitating combinatorial approaches that integrate tumor-specific antigens (e.g., carcinoembryonic antigen, CEA) or advanced imaging techniques to enhance screening precision. The gene discussed is CEACAM5; the disease is neoplasm.